Search results
Added:
2 months ago
SGLTi and GLP-1 in HF
Added:
1 year ago
Review Article
Added:
12 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more
Added:
1 year ago
In this short interview, Dr Scott Harris (Chief Medical Officer of AltImmune Inc.) joins us to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Dr Harris discusses the clinical need for these drugs, as well as an outline of the current evidence for the use of incretins in the…
View more
Added:
1 year ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design…
View more
Added:
7 months ago
EASD 2025 - Simultaneous finerenone and empagliflozin was a safe therapy option in patients with diabetes and chronic kidney disease (CKD).Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) joins us to discuss safety and efficacy findings from a double-blind, randomised, prespecified subanalysis of CONFIDENCE (NCT05254002), investigating simultaneous finerenone and…
View more
Added:
1 month ago
Source:
Radcliffe CVRM
While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have established cardiorenal benefits in type 2 diabetes, long-term data for their use in patients with type 1 diabetes (T1D) have been scarce. A new large-scale study suggests that initiating GLP-1RA therapy is associated with a lower risk of major adverse cardiovascular and kidney outcomes in this population, without compromising safety…
View more
Added:
2 weeks ago
Source:
Radcliffe CKM
Mirjam Boros, Radcliffe CardiologyA post hoc analysis of the SURPASS-CVOT trial suggests that tirzepatide, a dual GIP/GLP-1 receptor agonist, is associated with a lower incidence of a broad composite of cardiorenal events compared with the GLP-1 receptor agonist dulaglutide in patients with type 2 diabetes and established cardiovascular disease.¹Tirzepatide is a dual agonist that targets both…
View more
Added:
1 month ago
Source:
Radcliffe CVRM
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to reduce major atherosclerotic cardiovascular events, but the full extent of their mechanisms is still being explored. The SEMA-VR CardioLink-15 trial investigated whether semaglutide affects the levels of circulating vascular regenerative (VR) cells, which are involved in vessel repair and may modulate atherothrombotic risk.¹…
View more
Added:
9 months ago
Source:
Radcliffe CVRM
A new study has explored the underlying mechanisms by which semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), improves outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH).¹ The research, which combined analysis of a phase 2 clinical trial with preclinical models, identified a unique proteomic signature associated with treatment and suggests that…
View more